All quiet on the warfarin front

The revolution in warfarin care faces an uncertain future, with its proponent admitting he has no idea whether the government plans to act on his advice.

Professor Lloyd Sansom, who chaired the Federal Government's $400,000 anticoagulant review, said nine months later he was still in the dark on whether point-of-care INR testing, incentive payments and warfarin shared-care programs had any political traction.

"It's up